Clinical Trial

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

Study acronym: METRE-PL

Active, Not Recruiting Phase 3

Record status

This record was last updated June 15, 2026 (before its estimated July 21, 2026 completion). Its status may not reflect the trial's current state.

Summary

This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.

Protocol Amendment History 14 amendments

This ClinicalTrials.gov record has been amended 14 times since 2021-12-06; most recent amendment 2026-06-12.

Status change: Recruiting → Active, Not Recruiting 2025-08-25

Status change: Not Yet Recruiting → Recruiting 2022-02-15

Trial Details

NCT Number	NCT05164341
Lead Sponsor	Chiesi Farmaceutici S.p.A.
Conditions	Partial Lipodystrophy
Enrollment	69 participants
Start Date	2021-12-17
Primary Completion	2026-07-21 (estimated)
Study Completion	2026-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-15